PepGen (NASDAQ:PEPG - Free Report) had its price objective decreased by Bank of America from $10.00 to $6.00 in a research report released on Monday,Benzinga reports. Bank of America currently has a neutral rating on the stock.
A number of other equities analysts have also weighed in on PEPG. HC Wainwright reissued a "buy" rating and issued a $26.00 target price on shares of PepGen in a research report on Friday, November 8th. Wedbush reduced their price objective on PepGen from $19.00 to $12.00 and set an "outperform" rating for the company in a research note on Friday, November 8th.
View Our Latest Research Report on PepGen
PepGen Stock Performance
Shares of NASDAQ:PEPG traded up $0.01 during trading on Monday, reaching $4.13. 35,775 shares of the stock traded hands, compared to its average volume of 122,251. PepGen has a 52-week low of $3.90 and a 52-week high of $19.30. The stock has a market cap of $134.64 million, a P/E ratio of -1.38 and a beta of 1.76. The stock has a 50-day moving average of $8.03 and a two-hundred day moving average of $11.95.
Hedge Funds Weigh In On PepGen
Institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in PepGen by 68.0% during the 1st quarter. Vanguard Group Inc. now owns 850,445 shares of the company's stock valued at $12,502,000 after purchasing an additional 344,266 shares during the period. Acadian Asset Management LLC purchased a new stake in shares of PepGen in the 1st quarter valued at $30,000. Janus Henderson Group PLC boosted its holdings in PepGen by 18.1% in the first quarter. Janus Henderson Group PLC now owns 1,166,642 shares of the company's stock valued at $17,225,000 after purchasing an additional 178,438 shares during the last quarter. Artal Group S.A. acquired a new stake in PepGen during the first quarter worth about $2,940,000. Finally, RA Capital Management L.P. increased its holdings in shares of PepGen by 31.5% during the 1st quarter. RA Capital Management L.P. now owns 10,689,545 shares of the company's stock valued at $157,136,000 after purchasing an additional 2,557,593 shares in the last quarter. Hedge funds and other institutional investors own 58.01% of the company's stock.
PepGen Company Profile
(
Get Free Report)
PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.
Featured Stories
Before you consider PepGen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PepGen wasn't on the list.
While PepGen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
